BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06011577 (REL-1017 in major depressive disorder): BVCT ex-ante prediction vs. reported outcome

On 14 Jul 2024, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 9 Dec 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT06011577
Acronym
RELIGHT
Drug Name
REL-1017
Drug MoA
GLUN1-GLUN2D antagonist
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Mental Disorders
Indication
major depressive disorder (MDD)
Human Patients
340
Sponsor
Relmada Therapeutic
Phase
Phase 3

Prediction of , index 1679

Prospective Prediction
Prediction Index
1679
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient additive clinical benefit)
Technical Prediction
FAILURE (statistically insufficient additive clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
148 days in advance
Readout Data Interpretation
REL-1017 will be discontinued for lack of efficacy
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as an Adjunctive Treatment for Major Depressive Disorder (RELIGHT)
Phase
Phase 3
Status
Terminated
Enrollment
27
Lead sponsor
Levomecor Inc.
Conditions
Major Depressive Disorder; Depression
Interventions
DRUG: REL-1017; DRUG: Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2023-08-17
Primary completion
2024-12-19
Completion
2024-12-19
Results first posted
2026-07-10
Primary outcomes
  • Change From Baseline to Day 28 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score (Baseline and Day 28)

NCT06011577 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials